Arkitekt Ventures

Our portfolio company Jimini Health is hiring! Jimini Health is a 15-person Seed Stage company led by an experienced team of successful repeat entrepreneurs. They are building safe, human-in-the-loop, 24-7 patient-facing AI agents to radically improve Mental Health care, and are looking for Product, Backend, and AI positions. If you or anyone you know is interested, feel free to be in touch with Luis F Voloch

Excited to see our portfolio company CertifyOS new partnership with Candor Health to deliver next-gen precision and scalability in healthcare data accuracy.

This week, Anthropic launched Claude for Life Sciences, its first real push to make AI part of how science gets done. Why this matters 👇 - Scientists spend hours each week buried in docs and data. Claude aims to give them that time back by summarizing literature, drafting protocols, and analyzing data. And with prebuilt connectors to Benchling, BioRender, and PubMed, it fits well into existing workflows. - Some researchers have been eager to use AI but hesitant to apply it without clear benchmarks. Claude’s most capable model, Sonnet 4.5, shows strong performance in lab protocol and bioinformatics tasks, making AI adoption in the field more credible and comfortable. - Anthropic also introduced Agent Skills, instructions that dictate how Claude tackles specific tasks. The first skill they’ve built performs single-cell RNA sequencing quality control using scverse best practices, a sign they’re prioritizing technical rigor. It's a strong step forward, but the rollout points to where pharma still is on the AI adoption curve. Instead of the self serve model offered to consumers, Anthropic is partnering with consulting firms like Deloitte, Accenture and KPMG to bring Claude to enterprise pharma. I can't help but wonder, if the goal is to meet scientists where they are, why would it take a consulting team to get started? 🤔 WDYT? Image Credit: Anthropic Agent Skills, announcement link in comments

Yesterday Nabla Bio announced a up to $1B deal with Takeda signaling to the pharma industry: AI is no longer a nice to have, it's core infrastructure. Why this matters: 👇 - Historically, pharma has been cautious to bet big on AI in drug discovery. That hesitation has led to a wave of point solutions that predict, screen, or optimize a single step of the R&D process yielding almost insignificant value creation for AI x drug discovery startups. - Nabla’s deal hints at a bigger shift in the market, one where pharma moves from funding experimental pilots, or adopting point solutions, to forming integrated partnerships with significant upside for AI x drug discovery startups. - If this collaboration delivers, it's the business model we have been sorely missing. It could become the playbook for AI in drug discovery startups that want to build lasting businesses. Combined with AstraZeneca's $555 million bet earlier this month with Algen Biotechnologies to use machine learning for immunology targets, and Eli Lilly and Company up to $1.3B deal with Superluminal Medicines for its small molecule AI capabilities, this signals a clear shift towards real integration of AI-native drug development. Exciting times. #AIDrugDiscovery #Biotech #Pharma #GenerativeBiology #FoundationModels #DrugDevelopment Image credit: Biospace, article in comments

Proud to see our portfolio company Paradromics recognized by MassDevice as one of the top five BCI stories of 2025.

Congratulations to our Managing Director Enke Bashllari, Ph.D.  on joining the Board of Directors at Columbia University Mailman School of Public Health! A well-deserved recognition of her lifelong commitment to advancing human health and innovation.

I am truly honored to join the Board of Directors of Columbia University Mailman School of Public Health. I remember my PhD years at Columbia as some of the most intellectually rewarding ones. I was fortunate to have two Nobel Laureates and other stellar faculty teach me what scientific rigor and true excellence look like ( 👋 Prof. Axel and Prof. Kandel!). Just as important, I came to understand the role of innovation as a force for advancing human health. That pushed me to think critically about how to translate science into real impact, a mindset that guides how I work with founders building in health and bio today. Returning to Columbia in this capacity feels full circle. I look forward to working alongside the Board Dina Dublon, Sami Jarrah, Phyllis Mailman, Joshua Mailman, Chelsea Clinton, Rajiv Singh, Jean Drouin, Felicity Yost, Stacey Matlen, Thomas Campbell Jackson, Hannah Kellogg MPH, LEED-AP and many more, to support the school and its faculty in defining the next chapter of public health.

Thrilled to announce our investment in Standard Model Biomedicine as they emerge from stealth with a bold ambition: building a foundational model for all of biomedicine. Congratulations to Kevin Brown and the team! https://lnkd.in/g3DuYXwV

The next era of drug development is here. Standard Model Biomedicine came out of stealth yesterday with the world’s first universal patient model to help pharma make smarter, faster, and more analytically rigorous decisions across the entire R&D lifecycle. Despite hundreds of billions invested in drug discovery each year, most medicines still take a decade or more to reach patients in need. Standard Model Bio is changing that. Its framework, trained on billions of multimodal data points, can: - Inform Go/No-go decision on pipeline assets - Optimize clinical trial design - Identify high fit patients to boost trial enrollment - Build patient level reasoning engines to support active care decisions - And much, much more AI is already reducing timelines and costs for early adopters which is why Standard Model has secured partnerships with leading medical institutions and top pharma. Thrilled to be backing the infrastructure layer this industry desperately needs. From Day 0. Congrats to Kevin Brown, Arda Pekis, Zekai (Zach) Chen and the entire Standard Model team! CC Arkitekt Ventures Image Credit: Standard Model

Some news from Standard Model Biomedicine today: we’re officially out of stealth with three new papers. 🎉 🔗 http://bit.ly/46tdvRk 🔗 I founded Standard Model in 2024 with Arda Pekis and Zekai Chen, on the realization that patient data is naturally fragmented, and the resulting silos hold back biopharma and clinical progress. And so we dedicated ourselves to a shared vision: to build a best-in-class foundation model across all biomedical data. Coming out of stealth today is the culmination of hard work from our remarkable team, early partners, and investors—and this is just the beginning. Thank you to the people building and believing in our vision: 🔬 To our team, Erik Reinertsen, David Laub, David Laprade, Irsyad A., and Shaun Porwal: we’re only where we are today through your invaluable work. 🔥 To our investors, Arkitekt Ventures and Virtue : together, we are building the future of AI in biomedicine. Follow Standard Model Biomedicine on LinkedIn or subscribe to our new Substack to stay updated. We’ve got more to share in the coming weeks and months. The foundation for the future of biomedical research and drug development is being laid now, one datapoint at a time.